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Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is
characterized by progressive memory loss and cognitive decline. One of the hallmarks
of AD is the overproduction of amyloid-beta aggregates that range from the toxic
soluble oligomer (Aβo) form to extracellular accumulations in the brain. Growing evidence
indicates that mitochondrial dysfunction is a common feature of neurodegenerative
diseases and is observed at an early stage in the pathogenesis of AD. Reports indicate
that mitochondrial structure and function are affected by Aβo and can trigger neuronal
cell death. Mitochondria are highly dynamic organelles, and the balance between their
fusion and fission processes is essential for neuronal function. Interestingly, in AD, the
process known as “mitochondrial dynamics” is also impaired by Aβo. On the other hand,
the activation of the Wnt signaling pathway has an essential role in synaptic maintenance
and neuronal functions, and its deregulation has also been implicated in AD. We have
demonstrated that canonical Wnt signaling, through the Wnt3a ligand, prevents the
permeabilization of mitochondrial membranes through the inhibition of the mitochondrial
permeability transition pore (mPTP), induced by Aβo. In addition, we showed that non-
canonical Wnt signaling, through the Wnt5a ligand, protects mitochondria from fission-
fusion alterations in AD. These results suggest new approaches by which different Wnt
signaling pathways protect neurons in AD, and support the idea that mitochondria have
become potential therapeutic targets for the treatment of neurodegenerative disorders.
Here we discuss the neuroprotective role of the canonical and non-canonical Wnt
signaling pathways in AD and their differential modulation of mitochondrial processes,
associated with mitochondrial dysfunction and neurodegeneration.
Keywords: Wnt, mitochondrial dynamics, permeability transition, Alzheimer’s disease, amyloid-beta, Drp1,
electron microscopy
Abbreviations: Aβo, amyloid-beta oligomers; AD, Alzheimer’s disease; ANT, adenine nucleotide translocase; CMT, Charcot-
Mary-Tooth disease; CypD, cyclophilin D; ER, endoplasmic reticulum; GSK-3β, glycogen synthase-3 beta; HKII, hexokinase
II; IMM, inner mitochondrial membrane; IP3R, inositol triphosphate receptor; m∆Ψ, mitochondrial membrane potential;
MM, mitochondrial matrix; mPTP, mitochondrial permeability transition pore; OMM, outer mitochondrial membrane; PD,
Parkinson disease; PSD-95, postsynaptic density protein 95; ROS, reactive oxygen species; RyR, ryanodine receptor; SNCA,
α-synuclein; VDAC, voltage-dependent anion channel.
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Introduction
Mitochondria are key organelles for proper neuronal function
and viability, not only for their role in ATP production but
also for their tremendous capacity to buffer intracellular calcium
(Ca2+; Celsi et al., 2009). Due to this important function in
maintaining neuronal Ca2+ homeostasis, mitochondria have
been indicated in the regulation of synaptic transmission (Billups
and Forsythe, 2002). To perform this function, mitochondria
need to be mobile and to divide and fuse in order to enter
compartments where they are required for energy. These
include growth cones, axonal branches, presynaptic terminals
and dendritic spines (Morris and Hollenbeck, 1993; Ruthel
and Hollenbeck, 2003; Li et al., 2004). Since mitochondria are
involved in several essential processes of neuronal function,
pathological changes in mitochondrial dynamics, traffic or in
their structure directly affect mitochondrial function, not only
by failing to produce ATP and to buffer Ca2+ but also by
producing apoptotic cell death signals and contributing to
neurodegenerative diseases (Detmer and Chan, 2007; Su et al.,
2010; Sheng and Cai, 2012), such as Alzheimer’s disease (AD;
Eckert et al., 2003; Newmeyer and Ferguson-Miller, 2003). AD
is one of the most common causes of dementia worldwide
and mitochondrial dysfunction has been widely associated with
degeneration observed during the early stages of the disease
(Du et al., 2010; Swerdlow et al., 2010; Balietti et al., 2013). For
this reason we are interested in studying how we can protect
mitochondria to prevent the neuronal dysfunction observed in
AD. Moreover, one of the most important signaling cascades
described as being neuroprotective against amyloid-β peptide
(Aβ) in AD is the Wnt signaling pathway (De Ferrari and
Inestrosa, 2000; Cerpa et al., 2009; Inestrosa and Varela-Nallar,
2014), which has been deeply implicated in the development
and maintenance of the nervous system (Salinas and Zou,
2008; Inestrosa and Arenas, 2010; Rosso and Inestrosa, 2013).
Furthermore, Wnt signaling is differentially activated in neurons
to exert pre- or post-synaptic protective effects (Chacón et al.,
2008; Cerpa et al., 2010). Here, we propose to describe the
effects of canonical and non-canonical Wnt signaling activation
as a novel mechanism to protect mitochondria from common
defects associated with the pathogenesis of AD, such as impaired
mitochondrial dynamics, loss of calcium buffering capacity,
disruption of mitochondrial membranes through the induction
of the mitochondrial permeability transition pore (mPTP) and
the loss of their structure and function that finally produce
neuronal cell death in AD.
Alzheimer’s Disease
AD is one of the most common neurodegenerative disorders,
characterized by a progressive loss of memory and cognitive
decline (Hardy and Selkoe, 2002). At the neuropathological level,
brains of AD patients are characterized by the presence of senile
plaques, which are extracellular depositions of Aβ aggregates
(Mattson, 2004). Although it is not clearly known which is the
molecular triggering factor of the disease in most AD patients,
there are several studies suggesting that the Aβ peptide plays a key
pathogenic role (Hardy and Selkoe, 2002; Bates et al., 2009). Aβ
peptide is generated by the proteolytic processing of the amyloid
precursor protein (APP; Chow et al., 2010) and once it has
been produced, it can aggregate to form soluble species known
as Aβ oligomers (Aβo) and insoluble aggregates called amyloid
fibrils, which are the result of a higher state of aggregation
(Morgan et al., 2004; Ross and Poirier, 2005). Both aggregates
form senile plaques in AD brains (Sakono and Zako, 2010).
Despite the fact that Aβ fibrils are considered as the neurotoxic
species that apparently triggers AD (Hardy and Higgins, 1992;
Morgan et al., 2004) both in vivo and in vitro (Alvarez et al.,
2004; Dinamarca et al., 2006), currently, there is consensus that
Aβo could be the main cause of AD neurotoxicity, since they are
the species responsible for the synaptic dysfunction observed in
this pathology (Walsh et al., 2002; Cerpa et al., 2008; Li et al.,
2009). Recent studies have shown a strong correlation between
Aβo levels and the severity of synaptic and cognitive damage
(McLean et al., 1999; Ferreira et al., 2007; Haass and Selkoe,
2007), suggesting that Aβo are the main effectors of synaptic loss
and neuronal degeneration in AD (Lambert et al., 1998; Cleary
et al., 2005; Cerpa et al., 2008).
Besides synapses, Aβ presents several molecular and cellular
targets in neurons, contributing to the neuronal damage
that this peptide generates in AD. One of these targets
is Ca2+, which is a fundamental ion in the physiology
of neurons, since it modulates many neuronal processes,
including membrane excitability, neurotransmitter release, gene
expression, and neuronal growth and viability (LaFerla, 2002;
Bezprozvanny and Mattson, 2008). The balance between ion
influx and release modulates Ca2+ signaling. Ca2+ influx
across the plasma membrane occurs through voltage-gated Ca2+
channels, NMDA receptors and transient receptor potential
channels (Alford et al., 1993; Berridge, 1998). Ca2+ release
from intracellular Ca2+ stores occurs via inositol triphosphate
receptor (IP3R) and ryanodine receptor (RyR) channels in
the endoplasmic reticulum (ER; Marks, 1997). Moreover,
mitochondria also participate in the regulation of neuronal
Ca2+ levels through Ca2+ uptake, stimulating mitochondrial
metabolism and energy production (Babcock et al., 1997).
However, excessive calcium uptake into mitochondria can lead
to the opening of the permeability transition pore (PTP) and,
subsequently, to apoptosis (Spät et al., 2008; Celsi et al.,
2009).
During the slow progression of AD, the early phase of
memory loss is exacerbated by the onset of neuronal death,
which may also be driven by an increased deregulation of Ca2+
homeostasis (Demuro et al., 2010; Berridge, 2011). It has been
proposed that Aβ interaction with the plasma membrane results
in elevated intracellular Ca2+ concentrations and increased
vulnerability of neurons to excitotoxicity (Mattson et al., 1992).
The oligomeric forms of Aβ may increase Ca2+ entry by either
functioning as channels or by activating channels at the plasma
membrane such as the NMDA receptor (Dinamarca et al.,
2010; Berridge, 2011). The increase in cytosolic Ca2+ directly
affects mitochondria, disrupting their critical function as Ca2+
buffering organelles (Celsi et al., 2009), which disturbs ATP
generation and therefore neuronal viability. For this reason,
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mitochondrial dysfunction appears an obligatory downstream
step in the pathogenesis of AD.
Mitochondrial Deregulation in AD
Mitochondrial dysfunction is an early feature of AD since
several abnormalities have been described in brains from
different AD models (Moreira et al., 2007; Supnet and
Bezprozvanny, 2010; Swerdlow et al., 2010). The activity of
respiratory chain enzymes associated with the mitochondrial
complex III (cytochrome-c reductase) and IV (cytochrome-
c oxidase) is significantly decreased in mitochondria from
transgenic (Tg) APP mice (Caspersen et al., 2005; Manczak
et al., 2006) and in isolated mitochondria exposed to Aβ in
vitro (Canevari et al., 1999). Generation of reactive oxygen
species (ROS) is also deregulated in AD and an enhanced
production of free radicals and oxidative damage is a feature
of the progression of the disease (Reddy, 2006). In addition,
metabolic properties, such as ATP levels and glucose uptake
are also decreased in AD brains from Tg APP mice (Mosconi,
2005; Gauthier et al., 2006; Yao et al., 2009; Chen and Yan,
2010). The mitochondrial alterations triggered by Aβ creates
a negative environment for the maintenance of mitochondrial
function, since it directly affects the electrochemical gradient
that is generated along the electron transport chain (ETC),
favoring electron leakage and the production of superoxide
species, loss of mitochondrial membrane potential (m∆9),
permeability and structure disruption (Reddy, 2009). It has
been clearly demonstrated that Aβ accumulates progressively
within AD brains, Tg mouse models and cells overexpressing
APP (Lustbader et al., 2004; Devi et al., 2006; Du et al., 2008).
Aβ produced in the extracellular space enters neurons via the
endocytic pathway (Yu et al., 2010) and once amyloid-beta
oligomers (Aβo) are localized inside neurons, these oligomers
directly affect mitochondria. Mitochondrial accumulation of
Aβ could explain why Aβ dramatically interferes with the
function and structure of this organelle, thus affecting neuronal
viability.
Aβ accumulation in mitochondria occurs early in brains of
Tg APP mice, between 4–5 months old, and increases with
age, even before the massive extracellular deposition occurs
(Caspersen et al., 2005); an observation in agreement with
previous findings that indicate that intracellular accumulation
of Aβ occurs previously to amyloid plaque formation (Wirths
et al., 2001). The first study that described the presence of
Aβ in the mitochondria was by Lustbader et al. (2004). They
demonstrated that Aβ co-localized with the Aβ-binding alcohol
dehydrogenase (ABAD) inside mitochondria from human AD
brains, and that the interaction between Aβ and ABAD promotes
leakage of ROS, mitochondrial dysfunction and cell death
(Lustbader et al., 2004). It has been proposed that APP could
be located at the outer mitochondrial membrane (OMM)
where it can be processed by mitochondrial γ-secretase (Devi
and Anandatheerthavarada, 2010). The import of Aβ into
mitochondria has been observed both in vivo and in vitro and
occurs through the mitochondrial protein transport machinery,
specifically via the translocase of the OMM (TOM). This
phenomenon has been observed even when the Aβ peptide is
extracellularly added (Hansson Petersen et al., 2008), therefore,
mitochondrial Aβ accumulation is a key process, which leads to
the understanding of how Aβ can damage neurons so effectively
in AD. Once inside mitochondria, Aβ can interact with several
proteins that are important for the correct function of this
organelle and/or for the maintenance of its structure, such as
cyclophilin D (CypD), which participates in the opening of the
mPTP and therefore regulates the permeability and function
of mitochondria, affecting both their energetic and calcium
buffering functions (Connern and Halestrap, 1994; Du and Yan,
2010b).
The mPTP is a non-selective pore that remains open for
periods that are highly dependent on calcium concentration
inside the mitochondrial matrix (MM). Opening of the mPTP
for short time periods induces a rapid and regulated calcium
release from the MM (Halestrap, 2009). If the pore remains
open for longer periods of time, potentiated by an apoptotic
stimulus, such as Aβ, or by elevated calcium concentrations,
an uncontrolled release of this ion from the mitochondria
occurs (Muirhead et al., 2010; Rao et al., 2014). As a result,
the permeabilization of the inner mitochondrial membrane
(IMM) induces morphological changes in the mitochondria,
including increased volume, a phenomenon known as swelling,
and the dissipation of the m∆9 , disruption of membranes
and uncontrolled release of calcium and pro-apoptotic factors,
such as cytochrome-c, into the cytoplasm, activating neuronal
cell death cascades (Petronilli et al., 2001). Thus, blocking Aβ
action in mitochondria, and therefore its ability to induce mPTP
opening, are potential therapeutic strategies for AD. For this
reason, the study of molecules that could prevent mitochondrial
permeability induced by Aβ is crucial for the development of
tools for the early treatment of neurodegenerative diseases in
which mitochondria are involved.
Mitochondrial Dynamics in
Neurodegenerative Diseases
The mitochondrion is a highly dynamic organelle that can
migrate, split and merge. The regulation of these processes is
critical for normal cell function. Mitochondrial morphology
is very heterogeneous and may vary from small spheres to
interconnected tubules. These structural fluctuations are
regulated by the mitochondrial fission-fusion process, also
known as mitochondrial dynamics, which controls several
mitochondrial qualities and features, such as energy metabolism,
mitochondrial DNA content, and the shape and number of
mitochondria inside the cell (Hoppins et al., 2007). In addition
to these primary functions, several reports have demonstrated
that these dynamic processes are critical for the regulation of
cell death, mitophagy, and organelle distribution (Itoh et al.,
2013; Kornmann, 2014). A disruption in the balance between
mitochondrial fission and fusion processes is associated with
neurodegenerative diseases, such as AD, Parkinson’s disease
(PD) and Charcot-Mary-Tooth (CMT) disease type 2A (Detmer
and Chan, 2007; Schon and Przedborski, 2011; Yoon et al., 2011;
Burté et al., 2015).
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Mitochondrial fission is regulated by dynamin-related
protein 1, Drp1 (Kageyama et al., 2011; Tamura et al.,
2011), which is a cytosolic protein that assembles around
mitochondria to constrict and split them (Labrousse et al.,
1999; Smirnova et al., 2001). Drp1 is physiologically relevant
during the embryonic development of humans. A Drp1
mutation (A395D) that causes an impaired assembly of
Drp1 at mitochondria, leading to decreased fission, elongated
mitochondria, and their altered cellular distribution, was
correlated with microcephaly, abnormal development of the
brain and had lethal consequences in a newborn patient (Chang
et al., 2010).
In mammals, the mechanism of Drp1 translocation
to mitochondria is regulated by calcineurin-dependent
dephosphorylation (Cereghetti et al., 2008). Numerous
regulatory posttranslational modifications of Drp1 have
been reported including phosphorylation by PKC-δ (Qi
et al., 2011) and Cdk (Cdk1)/cyclin-B (Taguchi et al., 2007)
and nitrosylation (Barsoum et al., 2006). Ubiquitination
and sumoylation of Drp1 also regulate its stability and its
interaction with mitochondria (Chang and Blackstone, 2010;
Wilson et al., 2013). These modifications are essential for
controlling mitochondrial dynamics, since the deregulation in
the phosphorylation-dephosphorylation balance of Drp1 leads
to the loss of mitochondrial homeostasis and apoptosis (Cribbs
and Strack, 2007; Hoppins et al., 2007).
By contrast, mitochondrial fusion is regulated by two proteins
widely expressed in the OMM of the brain and other tissues,
known as mitofusin (Mfn) 1 and 2 (Rojo et al., 2002; Eura
et al., 2003). During this process, Mfn1 and 2 couple two
adjacent mitochondria to fuse both OMMs (Koshiba et al.,
2004), while the IMM fusion is mediated by the Opa1
protein (optic atrophy 1), which interacts with Mfns to fuse
both membranes (Cipolat et al., 2004; Song et al., 2009).
Pathological mutations inMfn2 andOpa1 impedemitochondrial
fusion, where Mfn2 causes the axonal CMT disease type
2A, which is characterized by the degeneration of retinal
ganglion cells and the optic nerve, and Opa1 causes autosomal
dominant optic atrophy, with the degeneration of peripheral
sensory and motor neurons (Westermann, 2010; Burté et al.,
2015).
In AD, Aβ overproduction causes an imbalance in
mitochondrial dynamics, affecting the levels of Drp1,
Opa1, Mfn1 and 2, both in vitro and in postmortem
brains of AD patients (Wang et al., 2008, 2009), inducing
mitochondrial fragmentation and an abnormal distribution
of mitochondria inside neurons. Despite the fact that the
mechanism of deregulation of mitochondrial dynamics in
AD is not completely understood, it is well known that the
activation state of Drp1 seems to be relevant (Cho et al.,
2009). Another possible mechanism, which also involves
Drp1, is the increased expression and interaction of Drp1
with Aβ and phosphorylated tau observed in AD patients
(Manczak et al., 2011; Manczak and Reddy, 2012). However,
the controversial evidence of Drp1 levels involved in AD
needs to be determined. Moreover, in brains from Tg2576
animals at the early stage of the disease, a reduced number
of synapses was observed, containing a higher number of
mitochondria, which were smaller in size (Balietti et al.,
2013), indicating an early vulnerability of this region to the
damage induced by Aβ. So, changes in mitochondrial dynamics
suggest a compensatory plastic mechanism to respond against
new energetic requirements that are necessary for synaptic
remodeling.
Besides AD, the dysfunctions of mitochondrial dynamics are
also a hallmark in the pathogenesis of several neurodegenerative
diseases such as PD. PD occurs mainly as a sporadic disease,
which is characterized by the intracellular accumulation of
α-synuclein (SNCA) protein. A lower proportion of PD is
produced by inherited genetic mutations, and its onset occurs
earlier than sporadic PD. Among the genes altered in PD
and that are associated with mitochondrial dysfunction, are
found α-synuclein, and leucine-rich repeat kinase 2 (LRRK2),
which are linked to autosomal-dominant PD. By contrast,
parkin and PTEN-induced putative kinase 1 (PINK) mutations
are linked to autosomal-recessive parkisonisms (Alberio et al.,
2012; Blandini and Armentero, 2012). Although no studies
have clearly established the causes of this disease, it has been
proposed that the overexpression of SNCA indirectly induces
mitochondrial fragmentation in neurons from a PD Tg mouse
model in vivo, by a mechanism independent to the fission-
fusion machinery (Xie and Chung, 2012). LRRK2 mutations are
the most common cause of familial and autosomal-dominant
PD. LRRK2 interacts with Drp1, inducing mitochondrial
fragmentation, which is increased in the presence of PD-
associated mutations, both in vitro and in vivo (Wang et al.,
2012; Burté et al., 2015). The PINK/Parkin pathway is known
to regulate homeostasis and mitochondrial quality control.
Studies in fibroblasts from patients with PD showed that Parkin
promotes mitochondrial elongation by degradation of Drp1
through its ubiquitination (Yan et al., 2013). However more
studies should be performed to clarify the discrepancies of
these results obtained between Drosophila and mammals (Exner
et al., 2007; Wang et al., 2011). This evidence shows a strong
relationship between disturbed mitochondrial dynamics and
neurodegeneration.
The Role of Wnt Signaling in
Neuroprotection
Previous studies from our laboratory have demonstrated that
the activation of the canonical Wnt signaling pathway protects
neurons against Aβ toxicity in vitro and in vivo (Alvarez et al.,
2004; Toledo and Inestrosa, 2010; Silva-Alvarez et al., 2013;
Vargas et al., 2014). The Wnt ligands are secreted proteins
that mainly activate two Wnt pathways: the canonical, or β-
catenin-dependent signaling pathway (Wnt/β-catenin); and the
non-canonical signaling pathways (Wnt/PCP and Wnt/Ca2+)
(Willert and Nusse, 2012; Inestrosa and Varela-Nallar, 2014).
The Wnt/PCP pathway is activated by the interaction of a Wnt
ligand with its Frizzled (Fz) receptor. This binding produces
the activation of Disheveled (Dvl), which in turn activates the
small GTPases Rho and Rac, to finally activate the Jun N-
terminal kinase (JNK), regulating cytoskeleton reorganization
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(Rosso et al., 2005). On the other hand, in the Wnt/Ca2+
pathway, the binding between a Wnt ligand and the Fz
receptor activates the trimeric G proteins, which induce the
activation of the phospholipase C (PLC) and the production of
diacylglycerol (DAG) and inositol triphosphate (IP3), generating
an increase in intracellular Ca2+ levels and the subsequent
activation of Ca2+-dependent proteins (Inestrosa and Arenas,
2010). By contrast, the Wnt/β-catenin pathway is activated by
the binding of a Wnt ligand to its Fz receptor and to the co-
receptor LRP5/6 (Willert and Nusse, 2012; Liu et al., 2014).
This interaction activates Dvl and causes the dissociation of the
destruction complex to inhibit the glycogen synthase kinase-
3β (GSK-3β) and to prevent β-catenin degradation through
the proteasome, inducing its accumulation into the cytoplasm,
which finally translocates to the nucleus and triggers the
expression of Wnt target genes (Arrázola et al., 2009; Clevers
and Nusse, 2012). Canonical Wnt signaling has been implicated
in neuroprotection against Aβ-induced neuronal damage (Cerpa
et al., 2009). In fact, its activation protects hippocampal
neurons from Aβ-induced cell death (Alvarez et al., 2004), and
also prevents the intracellular calcium increase generated by
Aβ in neurons, which directly affects mitochondrial calcium
levels (Quintanilla et al., 2005; Dinamarca et al., 2010). In
addition, we have demonstrated that the non-canonical Wnt
pathway, through its ligand Wnt5a, also has a neuroprotective
response against Aβ exposition through the modulation of
mitochondrial dynamics (Silva-Alvarez et al., 2013). However,
the mechanism by which this protection occurs is unknown.
Recently, our lab explored whether Wnt signaling could exert
its neuroprotective role against Aβ-induced toxicity through
the protection of the mitochondria (Arrázola and Inestrosa,
2013).
Protective Effects of the Different Wnt
Pathways
Canonical: Protects Mitochondria from
Permeability Transition
Wnt/β-catenin signaling activation has been involved in the
development and maintenance of the nervous system (Inestrosa
and Arenas, 2010; Inestrosa and Varela-Nallar, 2015) because
it regulates synaptogenesis (Salinas and Zou, 2008; Rosso and
Inestrosa, 2013) and participates in adult neurogenesis of the
hippocampus (Lie et al., 2005; Varela-Nallar and Inestrosa,
2013). Besides these critical functions in the physiology of
the central nervous system, the canonical Wnt pathway has
been associated with cell survival and neuroprotection (Oliva
et al., 2013; Harvey and Marchetti, 2014). For several years,
our laboratory has been studying the role of Wnt signaling
in the neurodegeneration observed in AD. The first time that
canonical Wnt signaling was associated with AD was by De
Ferrari and Inestrosa in 2000, where they proposed that sustained
loss of Wnt signaling function may lead to AD (De Ferrari and
Inestrosa, 2000; Inestrosa and Varela-Nallar, 2014). Later, they
showed that Aβ fibrils induced the destabilization of endogenous
levels of β-catenin, which were recovered with lithium (De
Ferrari et al., 2003), a pharmacological inhibitor of GSK-3β,
and therefore an inductor of Wnt signaling activation (Klein
and Melton, 1996). In addition, our laboratory demonstrated
that direct activation of the canonical Wnt signaling pathway,
through the Wnt3a ligand, prevents neuronal death induced by
Aβ fibrils and rescues β-catenin levels (Alvarez et al., 2004),
indicating that Wnt signaling activation plays a key role in
neuroprotection against Aβ-induced neuronal cell death (Cerpa
et al., 2009).
It is very well established that calcium plays an important
role in the neurotoxicity of AD in mouse models and in
vitro (LaFerla, 2002; Stutzmann et al., 2007), as it has been
demonstrated that Aβ aggregates, prepared from Aβ synthetic
peptides, induce intracellular calcium increase, which directly
impacts mitochondrial calcium levels (Dinamarca et al., 2010;
Supnet and Bezprozvanny, 2010). Previous studies with Wnt7a
indicated that this ligand prevents the intracellular calcium
increase generated by Aβ fibrils (Quintanilla et al., 2005)
and Aβ oligomers (Dinamarca et al., 2010) in hippocampal
neurons. These oligomers affect the calcium buffering function
of the mitochondria, as they produce calcium overload into
the organelle, however it has not been explored whether
Wnt signaling is able to prevent the calcium entrance
into mitochondria and if this process is involved in the
neuroprotective role of this signaling pathway against Aβ toxicity
in AD.
Regarding the calcium buffering function of the
mitochondria, it is well known that a massive and uncontrolled
calcium influx into mitochondria directly affects their
permeability (Du and Yan, 2010a) through mPTP opening
(Szalai et al., 1999). When the IMM is disrupted, because
of the formation of the mPTP, mitochondria undergo some
structural changes that finally affect its function and therefore,
the cellular decision between life or death (Newmeyer and
Ferguson-Miller, 2003). The loss of m∆9 and the release
of mitochondrial proapototic factors are events triggered by
mitochondrial swelling, which occurs during mPTP formation
and that enables the exchange of solutes between the cytoplasmic
compartment and MM, and viceversa, generating increased
volume of the organelle, membrane disruption and, finally,
the loss of mitochondrial function and cell death (Petronilli
et al., 2001). All of these events have been described in
AD as a consequence of the mitochondrial permeability
transition (Moreira et al., 2001) induced by Aβ-mediated
calcium variations (Celsi et al., 2009) or through a direct
interaction of Aβ with the mPTP protein complex (Du and Yan,
2010b).
The mPTP is mainly formed by three proteins: the voltage-
dependent anion channel (VDAC) at the OMM, adenine
nucleotide translocase (ANT) at the IMM, and CypD in the
MM; Baines et al., 2005; Schinzel et al., 2005; Halestrap, 2009).
VDAC is known as the mitochondrial porin and regulates cell
life and death, as it controls the entry an exit of mitochondrial
metabolites (Shoshan-Barmatz et al., 2010). ANT is an ADP/ATP
transporter, but is known to switch its function to a pore-
forming channel during apoptosis, regulating mPTP formation
(Tsujimoto and Shimizu, 2007; Singh et al., 2009). CypD is the
mitochondrial isoform of the peptidylprolyl cis- trans isomerase
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FIGURE 1 | Modulation of the mitochondrial permeability transition
pore structure. (A) The mPTP is mainly formed by the voltage-dependent
calcium channel (VDAC, in orange), adenine nucleotide translocase (ANT, in
purple) and cyclophilin D (CypD, in yellow). Under a physiological state, the
mPTP presents a reversible conformation and CypD is not part of the protein
complex and mainly resides into the mitochondrial matrix (MM). An interaction
of the components, triggered by an apoptotic stimulus, induces the formation
and opening of the mPTP, generating an irreversible response, that allows the
entry of water and solutes into the MM. (B) In the context of AD, Aβ oligomers
induce the translocation of CypD from the MM to the IMM to facilitate their
interaction with ANT, and therefore the formation and opening of the mPTP.
This final step induces uncontrolled release of calcium and mitochondrial
swelling.
cyclophilin chaperone family (Halestrap et al., 1997; Crompton
et al., 1998). CypD is the most important initiating molecule
for the mPTP, as it is a positive regulator required for mPTP
formation (Schinzel et al., 2005). CypD translocates to the
IMM during the opening of the pore under oxidative stress
conditions, interacting with ANT (Connern and Halestrap,
1994) and inducing the irreversible conformation of the mPTP
(Figure 1A). Regarding the action of Aβ on mPTP formation,
it is known that Aβ directly interacts with CypD, favoring
the formation of the pore, mitochondrial swelling and the
release of calcium from the mitochondria (Figure 1B; Du
et al., 2008). Thus, blocking the action of Aβ in mitochondria
and mPTP induction could be potential therapeutic strategies
against AD.
Recently, our laboratory showed the effect of the canonical
Wnt signaling activation on mPTP formation induced by Aβo.
Live cell imaging assays performed to evaluate mPTP induction
in situ in cultured hippocampal neurons (Gillessen et al., 2002;
Arrázola and Inestrosa, 2015) indicated that the canonical ligand
Wnt3a inhibits mPTP opening, induced by Aβo. We also
showed by electron microscopy from hippocampal slices that,
besides mPTP inhibition mediated by Wnt3a, this ligand can
also prevent the disruption of the mitochondrial membranes
and mitochondrial swelling, since the volume and size of the
organelle were conserved when Wnt signaling was activated,
preserving the whole structure of the mitochondria even in the
presence of Aβo (Arrázola and Inestrosa, 2013), and preventing
the changes that occur in AD brains during mPTP opening
(Moreira et al., 2001, 2002; Du and Yan, 2010b; Du et al.,
2010).
Pharmacological studies using ICG-001, an inhibitor of Wnt-
dependent gene transcription (Emami et al., 2004), allowed
us to determine that mPTP inhibition mediated by Wnt3a
was a β-catenin-independent effect (Arrázola and Inestrosa,
2013), indicating that Wnt modulates mPTP opening through
a mechanism that involves a divergent canonical Wnt signaling
pathway. According to this idea, it has been reported that GSK-
3β, one of the main components of the canonical Wnt signaling
pathway, is able to translocate to themitochondria and to interact
with ANT from the mPTP complex (Nishihara et al., 2007;
Gomez et al., 2008; Juhaszova et al., 2009). This interaction
has been described between ANT and the inhibited form of
GSK-3β (phosphorylated at serine 9), and it correlates with a
decrease in the CypD-ANT interaction, which is necessary for
mPTP opening (Miura et al., 2009; Zorov et al., 2009; Miura and
Tanno, 2010). Interestingly, canonical Wnt signaling activation
involves the phosphorylation of cytoplasmic GSK-3β at the same
residue (Ser-9), inhibiting the kinase (Stambolic and Woodgett,
1994) and surprisingly inducing the levels of phosphorylated-
GSK-3β at the mitochondria. Moreover, we observed that
this mitochondrial pool of phosphorylated-GSK-3β specifically
interacts with ANT and not with CypD, when Wnt signaling is
activated (Arrázola and Inestrosa, 2013), supporting the idea that
the mechanism by which Wnt3a inhibits mPTP opening could
be mediated by the modulation of mitochondrial GSK-3β; as has
been recently described in different models of mPTP induction
(Juhaszova et al., 2004; Nishihara et al., 2007; Miura and Tanno,
2010; Tanno et al., 2014).
On the other hand, several proteins have been described as
regulators of mPTP formation and all of them can interact with
some of the main components of the pore, or affect or facilitate
their interaction in order to modulate mitochondrial membrane
permeability and cell viability (Eliseev et al., 2009; Rasola et al.,
2010a; Saraiva et al., 2010). An example is the mitochondrial
hexokinase II (HKII) that when detached from the mitochondria
it induces mPTP formation and cell death (Chiara et al., 2008).
Mitochondrial HKII regulates mPTP induction through the
delivery of a survival signal that stabilizes the mPTP in the closed
conformation, whereas HKII detachment from mitochondria
would propagate a conformational change to molecules of
the inner mitochondrial membrane, eventually leading to pore
opening (Rasola et al., 2010b). Another mPTP modulator is
the survival kinase Akt, which regulates HKII by promoting
its binding to mitochondria, through HKII phosphorylation
(Miyamoto et al., 2008). Interestingly and in agreement with
our studies, Akt also inactivates GSK-3β by phosphorylation, a
fact that has been used in favor of the association of HKII to
the OMM, and therefore to the inhibition of mPTP opening.
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By contrast, activation of GSK-3β was shown to release HKII,
enhancing susceptibility to cell death (Robey and Hay, 2006).
Interestingly in AD, GSK-3β interacts with VDAC (Nishihara
et al., 2007), to dissociate HKII and Bcl-2 family proteins from
the complex and induces mitochondrial permeability transition
(Reddy, 2013). There are three known isoforms of VDAC in
mammals (De Pinto et al., 2010; Messina et al., 2012) and it
has been described that VDAC2 mediates the translocation of
GSK-3β to the mitochondria to trigger mPTP opening, as the
knockdown of VDAC2, but not VDAC1 or VDAC3, attenuates
both the mitochondrial translocation of GSK-3β and mPTP
opening under stress conditions (Tanno et al., 2014).
We have described that Wnt signaling activation increases
mitochondrial HKII levels (Arrázola and Inestrosa, 2013),
suggesting that the modulation of GSK-3β activity regulates
the recruitment of HKII to the mitochondria in response to
Wnt3a, reinforcing the idea that GSK-3β inhibition is a key
event in mPTP inhibition. This allows us to propose that the
Wnt signaling pathway controls the opening of the mPTP,
and prevents mitochondrial membrane permeability and the
subsequent collateral effects observed in AD (Figure 2).
Non-Canonical: Controls Mitochondrial
Dynamics
In the central nervous system, the non-canonical ligand
Wnt5a plays a key role in the regulation of the postsynaptic
compartment in neurons. It has been shown that Wnt5a
induces the clustering of the postsynaptic density protein
(PSD-95), through the activation of the Wnt/JNK pathway
(Farías et al., 2009), increasing the traffic and retention of the
GABAA receptor at the neuronal cell surface, an effect mediated
by CaMKII activation (Cuitino et al., 2010). These changes
FIGURE 2 | Consequences of mitochondrial permeability transition in
the AD brain: The role of canonical Wnt signaling in neuroprotection.
Mitochondria are structured organelles, which in normal or healthy conditions
(left panel) present a conserved structure of both the inner and outer
mitochondrial membranes. This organization allows the formation of the
mitochondrial cristae, which are important since therein resides the electron
transport chain to support cellular respiration and neuronal viability. Under AD
conditions (right panel), in the presence of Aβo, mitochondria undergo structural
changes as a result of Aβ-induced mitochondrial membrane permeability. This
phenomenon is triggered by the opening of the mitochondrial permeability
transition pore (mPTP), which produces water and solute entry into the
mitochondria, inducing increased mitochondrial volume and the loss of its
structure, promotes mitochondrial membrane potential (m∆9) dissipation and
the release of pro-apoptotic factors and calcium to the cytoplasm. These
morphological changes that mitochondria undergo during membrane
permeability are known as mitochondrial swelling, which finally generates the
loss of mitochondrial function to activate neuronal cell death processes. Bottom
panels show representative images obtained by electron microscopy of a
healthy mitochondrion (left) with normal membrane and cristae structures and
an AD mitochondrion (right) with disrupted membranes and cristae
disorganization as a result of mitochondrial swelling induced by Aβo. Canonical
Wnt signaling activation through the Wnt3a ligand prevents these morphological
and structural changes, preserving the integrity and function of the
mitochondria in the brain.
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promote the generation of new spines through a mechanism
that involves the activation of the Wnt/Ca2+ pathway (Varela-
Nallar et al., 2010), and a redistribution of mitochondria to
the spines, suggesting a new role for Wnt5a in the modulation
of the mitochondrial network and function (Godoy et al.,
2014).
There is evidence suggesting that the Wnt signaling pathway
participates in the regulation of mitochondrial dynamics and
function. Recently, we established that Wnt5a can avoid
mitochondrial loss in hippocampal neurons exposed to Aβ,
through the regulation of mitochondrial dynamics in vitro (Silva-
Alvarez et al., 2013). These effects are mediated by a Ca2+-
dependent mechanism that involves the IP3R and the RyR from
the ER. The relationship between mitochondrial fragmentation
and ER-mediated calcium release has been previously reported
in hippocampal neurons challenged with Aβo (Paula-Lima et al.,
2011) and 4-CMC, a direct agonist of RyR, that reproduced
the mitochondrial fragmentation effects observed with Aβo
(Paula-Lima et al., 2011; Sanmartin et al., 2012). However,
the mechanisms involved in the effects of Wnt5a on the
neuroprotection against Aβ remain to be determined. The
effects of Wnt5a on mitochondrial dynamics was recently
described (Godoy et al., 2014). Wnt5a induced an increase
of mitochondrial fission at the postsynaptic region, through
the increase of intracellular and mitochondrial Ca2+ levels,
and the regulation of Drp1 activity. In these conditions, the
calcium increase activates several kinases, such as, PKC and
calcineurin (Cereghetti et al., 2008; Qi et al., 2011) and our
results suggest that these enzymes could activate Drp1 to control
mitochondrial fission through Drp1 translocation from the
cytoplasm to theOMM (Figure 3). The increase inmitochondrial
number at the postsynaptic region suggests that Wnt5a might
act as a physiological regulator of mitochondrial dynamics
during synaptic function, collaborating with the energetic needs
of neurons, as has been demonstrated for the activation of
mitochondrial fission by Drp1 in dendritic spines (Li et al.,
2004).
Considering that neurons are highly polarized and have an
elevated demand of energy, mitochondrial distribution is critical
for the proper function of neuronal cells. In non-mitotic cells,
such as neurons, mitochondrial fission is particularly important
since it allows to create new mitochondria and contributes to
quality control by removing damaged mitochondria, facilitating
apoptosis against high levels of cell stress (Youle and van der
Bliek, 2012; Hoppins, 2014), such as in AD (Wang et al., 2008,
2009; Itoh et al., 2013; Silva-Alvarez et al., 2013). Interestingly, the
increment of fragmented mitochondria in hippocampal neurons
treated with Aβ dropped drastically after a short period of time,
suggesting the elimination of mitochondria mass as part of the
natural process of apoptosis against a major injury. This effect
was abolished with Wnt5a, which in the presence of Aβ also
caused an increase of fragmented mitochondria, and remained
constant over time (Silva-Alvarez et al., 2013). A possible
mechanism involved in Wnt5a neuroprotection in hippocampal
FIGURE 3 | Model of mitochondrial fission induced by the activation of
the non-canonical Wnt signaling pathway in dendritic spines.
Mitochondrial dynamics. Wnt5a ligand binds to its Fz receptor and activates
the Wnt/Ca2+ signaling pathway to promote mitochondrial fission in the
postsynaptic area. Wnt5a increases intracellular Ca2+, following the activation
of kinases (PKC and CaMKII) and phosphatases (calcineurin), which in turn
activates Drp1 through the regulation of its phosphorylation and
dephosphorylation states. Drp1 translocates from the cytoplasm to the
mitochondrial surface to induce mitochondrial fission. Mitochondrial
movement. The importance of the dendritic distribution of mitochondria in the
generation of new spines and synaptic plasticity has been established. Once
Drp1 is activated and induces mitochondrial fission, new mitochondria could
mobilize to dendritic spines to support the energy demands associated with
neural activity.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 May 2015 | Volume 9 | Article 166
Arrázola et al. Wnt protects against mitochondrial damage
neurons exposed to Aβ might be due to the increasing
mitochondrial Ca2+ levels triggered by this ligand (Silva-Alvarez
et al., 2013; Godoy et al., 2014). Neuronal mitochondria have
a fundamental and strategic spatial distribution to buffer the
increase of Ca2+. The presence of mitochondria in the vicinity of
Ca2+ channels, such as NMDA receptors, allows mitochondrial
Ca2+ incorporation and prevents mass propagation of cytosolic
Ca2+ (Billups and Forsythe, 2002; Medler and Gleason, 2002).
Clearly, increasing the buffering ability of mitochondria is
essential for proper neuronal function, particularly in areas
of high nervous activity. The stimulation of mitochondrial
fission through Wnt5a would provide the energy requirements
needed during nerve activity and, moreover, its effect on
the buffer capacity of Ca2+ in mitochondria could protect
neurons from the toxicity associated with the uncontrolled
increase of intracellular Ca2+ levels produced during synaptic
activity.
Conclusion
Energy metabolism is a key process for the normal function
of the body, mainly in the brain, an organ with high-energy
dependency. In energy production, mitochondria play a
central role, which is demonstrated by the diverse alterations
of mitochondrial functions described in neurodegenerative
diseases, such as AD, where deregulation of mitochondrial
function is directly correlated with different pathological
processes including decreased brain metabolism, alterations
in mitochondrial structure, deregulation of regulatory
enzyme activity, increased oxidative stress and increased
levels of mitochondrial Aβ. Together, these changes have
been proposed as markers of AD pathogenesis, with special
focus on mitochondrial physiology. An interesting aspect
of AD is the close relationship between the damage caused
by the accumulation of amyloid plaques and mitochondrial
dysfunction. Several studies have reported that the Aβ peptide
can directly interact with the mitochondrial membrane
promoting the opening of the mPTP, which triggers a
deregulation in Ca2+ levels, leading to the dysfunction of
several neuronal processes, irreversible failure of synaptic
transmission and finally to neuronal cell death. In recent
years, several groups have proposed that deregulation of the
mitochondrial fission-fusion processes could play a key role
in the initiation and progression of various neurodegenerative
diseases, positioning itself as a possible common mechanism for
the observed neuronal death in these pathologies and becoming
an interesting therapeutic target. The search of strategies that
could prevent the opening of the mPTP and the description of
signaling pathways that can regulate mitochondrial dynamics,
represent the first step in developing therapeutic strategies.
In this regardor laboratory has described key evidence about
the role of the Wnt signaling pathway in neuroprotection
against Aβ and in the regulation of mitochondrial dynamics.
Considering that Wnt signaling has been proposed as a critical
pathway in neurodegeneration, this interaction could represent
an interesting field of study in the search for drugs capable of
reversing mitochondrial dysfunction and in this way avoid or
revert the onset and progression of neurodegenerative diseases.
References
Alberio, T., Lopiano, L., and Fasano, M. (2012). Cellular models to investigate
biochemical pathways in Parkinson’s disease. FEBS J. 279, 1146–1155. doi: 10.
1111/j.1742-4658.2012.08516.x
Alford, S., Frenguelli, B. G., Schofield, J. G., and Collingridge, G. L. (1993).
Characterization of Ca2+ signals induced in hippocampal CA1 neurones by
the synaptic activation of NMDA receptors. J. Physiol. 469, 693–716. doi: 10.
1113/jphysiol.1993.sp019838
Alvarez, A. R., Godoy, J. A., Mullendorff, K., Olivares, G. H., Bronfman, M.,
and Inestrosa, N. C. (2004). Wnt-3a overcomes beta-amyloid toxicity in rat
hippocampal neurons. Exp. Cell Res. 297, 186–196. doi: 10.1016/j.yexcr.2004.
02.028
Arrázola,M. S., and Inestrosa, N. C. (2013). ‘‘Wnt3a ligand preventsmitochondrial
permeability transition pore opening induced by Aβ oligomers,’’ in Program
of the XXVII Annual Meeting of the Chilean Society for Cell Biology (Puerto
Varas–Chile), 23–27.
Arrázola, M. S., and Inestrosa, N. C. (2015). ‘‘Monitoring mitochondrial
membranes permeability in live neurons and mitochondrial swelling through
electron microscopy analysis,’’ in Neuronal Cell Death. Methods in Molecular
Biology (Vol. 1254), eds L. Lossi and A. Merighi (New York: Springer),
87–97.
Arrázola, M. S., Varela-Nallar, L., Colombres, M., Toledo, E. M., Cruzat, F., Pavez,
L., et al. (2009). Calcium/calmodulin-dependent protein kinase type IV is a
target gene of the Wnt/beta-catenin signaling pathway. J. Cell. Physiol. 221,
658–667. doi: 10.1002/jcp.21902
Babcock, D. F., Herrington, J., Goodwin, P. C., Park, Y. B., and Hille, B. (1997).
Mitochondrial participation in the intracellular Ca2+ network. J. Cell Biol. 136,
833–844. doi: 10.1083/jcb.136.4.833
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton,
M. A., et al. (2005). Loss of cyclophilin D reveals a critical role for
mitochondrial permeability transition in cell death. Nature 434, 658–662.
doi: 10.1038/nature03434
Balietti, M., Giorgetti, B., Casoli, T., Solazzi, M., Tamagnini, F., Burattini,
C., et al. (2013). Early selective vulnerability of synapses and synaptic
mitochondria in the hippocampal CA1 region of the Tg2576 mouse model
of Alzheimer’s disease. J. Alzheimers Dis. 34, 887–896. doi: 10.3233/JAD-
121711
Barsoum, M. J., Yuan, H., Gerencser, A. A., Liot, G., Kushnareva, Y., Gräber,
S., et al. (2006). Nitric oxide-induced mitochondrial fission is regulated by
dynamin-related GTPases in neurons. EMBO J. 25, 3900–3911. doi: 10.1038/sj.
emboj.7601253
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L.,
et al. (2009). Clearance mechanisms of Alzheimer’s amyloid-beta peptide:
implications for therapeutic design and diagnostic tests. Mol. Psychiatry 14,
469–486. doi: 10.1038/mp.2008.96
Berridge, M. J. (1998). Neuronal calcium signaling. Neuron 21, 13–26. doi: 10.
1016/s0896-6273(00)80510-3
Berridge, M. J. (2011). Calcium signalling and Alzheimer’s disease. Neurochem.
Res. 36, 1149–1156. doi: 10.1007/s11064-010-0371-4
Bezprozvanny, I., and Mattson, M. P. (2008). Neuronal calcium mishandling and
the pathogenesis of Alzheimer’s disease. Trends Neurosci. 31, 454–463. doi: 10.
1016/j.tins.2008.06.005
Billups, B., and Forsythe, I. D. (2002). Presynaptic mitochondrial calcium
sequestration influences transmission at mammalian central synapses. J.
Neurosci. 22, 5840–5847.
Blandini, F., and Armentero, M.-T. (2012). Animal models of Parkinson’s
disease. FEBS J. 279, 1156–1166. doi: 10.1111/j.1742-4658.2012.
08491.x
Burté, F., Carelli, V., Chinnery, P. F., and Yu-Wai-Man, P. (2015). Disturbed
mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol.
11, 11–24. doi: 10.1038/nrneurol.2014.228
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 May 2015 | Volume 9 | Article 166
Arrázola et al. Wnt protects against mitochondrial damage
Canevari, L., Clark, J. B., and Bates, T. E. (1999). β-Amyloid fragment 25–35
selectively decreases complex IV activity in isolated mitochondria. FEBS Lett.
457, 131–134. doi: 10.1016/s0014-5793(99)01028-5
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., et al.
(2005). Mitochondrial Aβ: a potential focal point for neuronal metabolic
dysfunction in Alzheimer’s disease. FASEB J. 19, 2040–2041. doi: 10.1096/fj.05-
3735fje
Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., et al. (2009).
Mitochondria, calcium and cell death: a deadly triad in neurodegeneration.
Biochim. Biophys. Acta 1787, 335–344. doi: 10.1016/j.bbabio.2009.
02.021
Cereghetti, G. M., Stangherlin, A., Martins de Brito, O., Chang, C. R., Blackstone,
C., Bernardi, P., et al. (2008). Dephosphorylation by calcineurin regulates
translocation of Drp1 to mitochondria. Proc. Natl. Acad. Sci. U S A 105,
15803–15808. doi: 10.1073/pnas.0808249105
Cerpa, W., Dinamarca, M. C., and Inestrosa, N. C. (2008). Structure-function
implications in Alzheimer’s disease: effect of Aβ oligomers at central synapses.
Curr. Alzheimer Res. 5, 233–243. doi: 10.2174/156720508784533321
Cerpa, W., Farías, G. G., Godoy, J. A., Fuenzalida, M., Bonansco, C., and
Inestrosa, N. C. (2010). Wnt-5a occludes Aβ oligomer-induced depression of
glutamatergic transmission in hippocampal neurons. Mol. Neurodegener. 5:3.
doi: 10.1186/1750-1326-5-3
Cerpa, W., Toledo, E. M., Varela-Nallar, L., and Inestrosa, N. C. (2009). The role
of Wnt signaling in neuroprotection. Drug News Perspect. 22, 579–591. doi: 10.
1358/dnp.2009.10.1436817
Chacón,M. A., Varela-Nallar, L., and Inestrosa, N. C. (2008). Frizzled-1 is involved
in the neuroprotective effect of Wnt3a against Aβ oligomers. J. Cell. Physiol.
217, 215–227. doi: 10.1002/jcp.21497
Chang, C.-R., and Blackstone, C. (2010). Dynamic regulation of mitochondrial
fission through modification of the dynamin-related protein Drp1. Ann. N Y
Acad. Sci. 1201, 34–39. doi: 10.1111/j.1749-6632.2010.05629.x
Chang, C.-R., Manlandro, C. M., Arnoult, D., Stadler, J., Posey, A. E., Hill, R. B.,
et al. (2010). A lethal de novo mutation in the middle domain of the dynamin-
related GTPase Drp1 impairs higher order assembly and mitochondrial
division. J. Biol. Chem. 285, 32494–32503. doi: 10.1074/jbc.m110.142430
Chen, J. X., and Yan, S. S. (2010). Role of mitochondrial amyloid-beta in
Alzheimer’s disease. J. Alzheimers Dis. 20(Suppl. 2), S569–S578. doi: 10.
3233/JAD-2010-100357
Chiara, F., Castellaro, D., Marin, O., Petronilli, V., Brusilow, W. S., Juhaszova,
M., et al. (2008). Hexokinase II detachment from mitochondria triggers
apoptosis through the permeability transition pore independent of voltage-
dependent anion channels. PLoS One 3:e1852. doi: 10.1371/journal.pone.00
01852
Cho, D.-H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., et al. (2009). S-
nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and
neuronal injury. Science 324, 102–105. doi: 10.1126/science.1171091
Chow, V. W., Mattson, M. P., Wong, P. C., and Gleichmann, M. (2010). An
overview of APP processing enzymes and products. Neuromolecular Med. 12,
1–12. doi: 10.1007/s12017-009-8104-z
Cipolat, S., Martins de Brito, O., Dal Zilio, B., and Scorrano, L. (2004). OPA1
requires mitofusin 1 to promote mitochondrial fusion. Proc. Natl. Acad. Sci.
U S A 101, 15927–15932. doi: 10.1073/pnas.0407043101
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski,
M. A., Selkoe, D. J., et al. (2005). Natural oligomers of the amyloid-beta
protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79–84. doi: 10.
1038/nn1372
Clevers, H., and Nusse, R. (2012). Wnt/β-catenin signaling and disease. Cell 149,
1192–1205. doi: 10.1016/j.cell.2012.05.012
Connern, C. P., and Halestrap, A. P. (1994). Recruitment of mitochondrial
cyclophilin to the mitochondrial inner membrane under conditions of
oxidative stress that enhance the opening of a calcium-sensitive non-specific
channel. Biochem. J. 302(Pt. 2), 321–324.
Cribbs, J. T., and Strack, S. (2007). Reversible phosphorylation of Drp1 by cyclic
AMP-dependent protein kinase and calcineurin regulatesmitochondrial fission
and cell death. EMBO Rep. 8, 939–944. doi: 10.1038/sj.embor.7401062
Crompton, M., Virji, S., and Ward, J. M. (1998). Cyclophilin-D binds strongly to
complexes of the voltage-dependent anion channel and the adenine nucleotide
translocase to form the permeability transition pore. Eur. J. Biochem. 258,
729–735. doi: 10.1046/j.1432-1327.1998.2580729.x
Cuitino, L., Godoy, J. A., Farías, G. G., Couve, A., Bonansco, C., Fuenzalida, M.,
et al. (2010). Wnt-5a modulates recycling of functional GABAA receptors on
hippocampal neurons. J. Neurosci. 30, 8411–8420. doi: 10.1523/JNEUROSCI.
5736-09.2010
De Ferrari, G. V., Chacón, M. A., Barría, M. I., Garrido, J. L., Godoy, J. A., Olivares,
G., et al. (2003). Activation of Wnt signaling rescues neurodegeneration and
behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8,
195–208. doi: 10.1038/sj.mp.4001208
De Ferrari, G. V., and Inestrosa, N. C. (2000). Wnt signaling function in
Alzheimer’s disease. Brain Res. Brain Res. Rev. 33, 1–12. doi: 10.1016/S0165-
0173(00)00021-7
Demuro, A., Parker, I., and Stutzmann, G. E. (2010). Calcium signaling and
amyloid toxicity in Alzheimer disease. J. Biol. Chem. 285, 12463–12468. doi: 10.
1074/jbc.R109.080895
De Pinto, V., Guarino, F., Guarnera, A., Messina, A., Reina, S., Tomasello, F. M.,
et al. (2010). Characterization of human VDAC isoforms: a peculiar function
for VDAC3? Biochim. Biophys. Acta 1797, 1268–1275. doi: 10.1016/j.bbabio.
2010.01.031
Detmer, S. A., and Chan, D. C. (2007). Functions and dysfunctions of
mitochondrial dynamics. Nat. Rev. Mol. Cell Biol. 8, 870–879. doi: 10.
1038/nrm2275
Devi, L., and Anandatheerthavarada, H. K. (2010). Mitochondrial trafficking
of APP and alpha synuclein: relevance to mitochondrial dysfunction in
Alzheimer’s and Parkinson’s diseases. Biochim. Biophys. Acta 1802, 11–19.
doi: 10.1016/j.bbadis.2009.07.007
Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., and Anandatheerthavarada,
H. K. (2006). Accumulation of amyloid precursor protein in the mitochondrial
import channels of human Alzheimer’s disease brain is associated with
mitochondrial dysfunction. J. Neurosci. 26, 9057–9068. doi: 10.1523/jneurosci.
1469-06.2006
Dinamarca,M. C., Cerpa,W., Garrido, J., Hancke, J. L., and Inestrosa, N. C. (2006).
Hyperforin prevents β-amyloid neurotoxicity and spatial memory impairments
by disaggregation of Alzheimer’s amyloid-beta-deposits. Mol. Psychiatry 11,
1032–1048. doi: 10.1038/sj.mp.4001866
Dinamarca, M. C., Sagal, J. P., Quintanilla, R. A., Godoy, J. A., Arrázola, M. S., and
Inestrosa, N. C. (2010). Amyloid-β-Acetylcholinesterase complexes potentiate
neurodegenerative changes induced by the Aβ peptide. Implications for the
pathogenesis of Alzheimer’s disease.Mol. Neurodegener. 5:4. doi: 10.1186/1750-
1326-5-4
Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., et al. (2008).
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation
and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 14,
1097–1105. doi: 10.1038/nm.1868
Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., and Yan, S. S.
(2010). Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse
model. Proc. Natl. Acad. Sci. U S A 107, 18670–18675. doi: 10.1073/pnas.10065
86107
Du, H., and Yan, S. S. (2010a). Mitochondrial medicine for neurodegenerative
diseases. Int. J. Biochem. Cell Biol. 42, 560–572. doi: 10.1016/j.biocel.2010.01.
004
Du, H., and Yan, S. S. (2010b). Mitochondrial permeability transition pore in
Alzheimer’s disease: cyclophilin D and amyloid beta. Biochim. Biophys. Acta
1802, 198–204. doi: 10.1016/j.bbadis.2009.07.005
Eckert, A., Keil, U., Marques, C. A., Bonert, A., Frey, C., Schüssel, K., et al. (2003).
Mitochondrial dysfunction, apoptotic cell death and Alzheimer’s disease.
Biochem. Pharmacol. 66, 1627–1634. doi: 10.1016/s0006-2952(03)00534-3
Eliseev, R. A., Malecki, J., Lester, T., Zhang, Y., Humphrey, J., and Gunter, T. E.
(2009). Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect. J.
Biol. Chem. 284, 9692–9699. doi: 10.1074/jbc.M808750200
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M.,
et al. (2004). A small molecule inhibitor of beta-catenin/CREB-binding protein
transcription. Proc. Natl. Acad. Sci. U S A 101, 12682–12687. doi: 10.1073/pnas.
0404875101
Eura, Y., Ishihara, N., Yokota, S., and Mihara, K. (2003). Two mitofusin
proteins, mammalian homologues of FZO, with distinct functions are both
required for mitochondrial fusion. J. Biochem. 134, 333–344. doi: 10.1093/jb/
mvg150
Exner, N., Treske, B., Paquet, D., Holmström, K., Schiesling, C., Gispert, S.,
et al. (2007). Loss-of-function of human PINK1 results in mitochondrial
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 May 2015 | Volume 9 | Article 166
Arrázola et al. Wnt protects against mitochondrial damage
pathology and can be rescued by parkin. J. Neurosci. 27, 12413–12418. doi: 10.
1523/jneurosci.0719-07.2007
Farías, G. G., Alfaro, I. E., Cerpa, W., Grabowski, C. P., Godoy, J. A., Bonansco,
C., et al. (2009). Wnt-5a/JNK signaling promotes the clustering of PSD-95
in hippocampal neurons. J. Biol. Chem. 284, 15857–15866. doi: 10.1074/jbc.
m808986200
Ferreira, S. T., Vieira, M. N. N., and De Felice, F. G. (2007). Soluble protein
oligomers as emerging toxins in Alzheimer’s and other amyloid diseases.
IUBMB Life 59, 332–345. doi: 10.1080/15216540701283882
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K.,
et al. (2006). Mild cognitive impairment. Lancet 367, 1262–1270. doi: 10.
1016/S0140-6736(06)68542-5
Gillessen, T., Grasshoff, C., and Szinicz, L. (2002). Mitochondrial permeability
transition can be directly monitored in living neurons. Biomed. Pharmacother.
56, 186–193. doi: 10.1016/s0753-3322(02)00184-1
Godoy, J. A., Arrázola, M. S., Ordenes, D., Silva-Alvarez, C., Braidy, N., and
Inestrosa, N. C. (2014). Wnt-5a ligand modulates mitochondrial fission-fusion
in rat hippocampal neurons. J. Biol. Chem. 289, 36179–36193. doi: 10.1074/jbc.
M114.557009
Gomez, L., Paillard, M., Thibault, H., Derumeaux, G., and Ovize, M. (2008).
Inhibition of GSK3beta by postconditioning is required to prevent opening of
the mitochondrial permeability transition pore during reperfusion. Circulation
117, 2761–2768. doi: 10.1161/CIRCULATIONAHA.107.755066
Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in
neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide.
Nat. Rev. Mol. Cell Biol. 8, 101–112. doi: 10.1038/nrm2101
Halestrap, A. P. (2009). What is the mitochondrial permeability transition
pore? J. Mol. Cell. Cardiol. 46, 821–831. doi: 10.1016/j.yjmcc.2009.
02.021
Halestrap, A. P., Connern, C. P., Griffiths, E. J., and Kerr, P.M. (1997). Cyclosporin
A binding to mitochondrial cyclophilin inhibits the permeability transition
pore and protects hearts from ischaemia/reperfusion injury.Mol. Cell. Biochem.
174, 167–172. doi: 10.1007/978-1-4615-6111-8_25
Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov,
P. F., Alafuzoff, I., et al. (2008). The amyloid beta-peptide is imported into
mitochondria via the TOM import machinery and localized to mitochondrial
cristae. Proc. Natl. Acad. Sci. U S A 105, 13145–13150. doi: 10.1073/pnas.
0806192105
Hardy, J. A., and Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256, 184–185. doi: 10.1126/science.1566067
Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 297, 353–356.
doi: 10.1126/science.1072994
Harvey, K., and Marchetti, B. (2014). Regulating Wnt signaling: a strategy to
prevent neurodegeneration and induce regeneration. J. Mol. Cell Biol. 6, 1–2.
doi: 10.1093/jmcb/mju002
Hoppins, S. (2014). The regulation of mitochondrial dynamics. Curr. Opin. Cell
Biol. 29, 46–52. doi: 10.1016/j.ceb.2014.03.005
Hoppins, S., Lackner, L., and Nunnari, J. (2007). The machines that divide and
fuse mitochondria. Annu. Rev. Biochem. 76, 751–780. doi: 10.1146/annurev.
biochem.76.071905.090048
Inestrosa, N. C., and Arenas, E. (2010). Emerging roles of Wnts in the adult
nervous system. Nat. Rev. Neurosci. 11, 77–86. doi: 10.1038/nrn2755
Inestrosa, N. C., and Varela-Nallar, L. (2014). Wnt signaling in the nervous system
and in Alzheimer’s disease. J. Mol. Cell Biol. 6, 64–74. doi: 10.1093/jmcb/
mjt051
Inestrosa, N. C., and Varela-Nallar, L. (2015). Wnt signalling in neuronal
differentiation and development. Cell Tissue Res. 359, 215–223. doi: 10.
1007/s00441-014-1996-4
Itoh, K., Nakamura, K., Iijima, M., and Sesaki, H. (2013). Mitochondrial dynamics
in neurodegeneration. Trends Cell Biol. 23, 64–71. doi: 10.1016/j.tcb.2012.
10.006
Juhaszova, M., Zorov, D. B., Kim, S., Pepe, S., Fu, Q., Fishbein, K. W., et al. (2004).
Glycogen synthase kinase-3β mediates convergence of protection signaling to
inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 113,
1535–1549. doi: 10.1172/JCI200419906
Juhaszova, M., Zorov, D. B., Yaniv, Y., Nuss, H. B., Wang, S., and Sollott, S. J.
(2009). Role of glycogen synthase kinase-3beta in cardioprotection. Circ. Res.
104, 1240–1252. doi: 10.1161/CIRCRESAHA.109.197996
Kageyama, Y., Zhang, Z., and Sesaki, H. (2011). Mitochondrial division: molecular
machinery and physiological functions. Curr. Opin. Cell Biol. 23, 427–434.
doi: 10.1016/j.ceb.2011.04.009
Klein, P. S., and Melton, D. A. (1996). A molecular mechanism for the effect of
lithium on development. Proc. Natl. Acad. Sci. U S A 93, 8455–8459. doi: 10.
1073/pnas.93.16.8455
Kornmann, B. (2014). Quality control in mitochondria: use it, break it, fix it, trash
it. F1000Prime Rep. 6:15. doi: 10.12703/P6-15
Koshiba, T., Detmer, S. A., Kaiser, J. T., Chen, H.,McCaffery, J.M., andChan, D. C.
(2004). Structural basis of mitochondrial tethering by mitofusin complexes.
Science 305, 858–862. doi: 10.1126/science.1099793
Labrousse, A. M., Zappaterra, M. D., Rube, D. A., and van der Bliek, A. M.
(1999). C. elegans dynamin-related protein DRP-1 controls severing of the
mitochondrial outer membrane. Mol. Cell 4, 815–826. doi: 10.1016/s1097-
2765(00)80391-3
LaFerla, F. M. (2002). Calcium dyshomeostasis and intracellular signalling in
Alzheimer’s disease. Nat. Rev. Neurosci. 3, 862–872. doi: 10.1038/nrn960
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos,
M., et al. (1998). Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent
central nervous system neurotoxins. Proc. Natl. Acad. Sci. U S A 95, 6448–6453.
doi: 10.1073/pnas.95.11.6448
Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., and Selkoe, D.
(2009). Soluble oligomers of amyloid beta protein facilitate hippocampal long-
term depression by disrupting neuronal glutamate uptake.Neuron 62, 788–801.
doi: 10.1016/j.neuron.2009.05.012
Li, Z., Okamoto, K.-I., Hayashi, Y., and Sheng, M. (2004). The importance of
dendritic mitochondria in the morphogenesis and plasticity of spines and
synapses. Cell 119, 873–887. doi: 10.1016/j.cell.2004.11.003
Lie, D.-C., Colamarino, S. A., Song, H.-J., Désiré, L., Mira, H., Consiglio, A., et al.
(2005). Wnt signalling regulates adult hippocampal neurogenesis. Nature 437,
1370–1375. doi: 10.1038/nature04108
Liu, C.-C., Tsai, C.-W., Deak, F., Rogers, J., Penuliar, M., Sung, Y. M., et al.
(2014). Deficiency in LRP6-mediated Wnt signaling contributes to synaptic
abnormalities and amyloid pathology in Alzheimer’s disease.Neuron 84, 63–77.
doi: 10.1016/j.neuron.2014.08.048
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K.,Wang, N., et al. (2004).
ABAD directly links Aβ to mitochondrial toxicity in Alzheimer’s disease.
Science 304, 448–452. doi: 10.1126/science.1091230
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., and Reddy,
P. H. (2006). Mitochondria are a direct site of A beta accumulation in
Alzheimer’s disease neurons: implications for free radical generation and
oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437–1449.
doi: 10.1093/hmg/ddl066
Manczak, M., Calkins, M. J., and Reddy, P. H. (2011). Impaired mitochondrial
dynamics and abnormal interaction of amyloid beta with mitochondrial
protein Drp1 in neurons from patients with Alzheimer’s disease:
implications for neuronal damage. Hum. Mol. Genet. 20, 2495–2509. doi: 10.
1093/hmg/ddr139
Manczak, M., and Reddy, P. H. (2012). Abnormal interaction between
the mitochondrial fission protein Drp1 and hyperphosphorylated tau in
Alzheimer’s disease neurons: implications for mitochondrial dysfunction and
neuronal damage. Hum. Mol. Genet. 21, 2538–2547. doi: 10.1093/hmg/dds072
Marks, A. R. (1997). Intracellular calcium-release channels: regulators of cell life
and death. Am. J. Physiol. 272, H597–H605.
Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease.
Nature 430, 631–639. doi: 10.1038/nature02621
Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E.
(1992). β-Amyloid peptides destabilize calcium homeostasis and render human
cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376–389.
McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther,
K., et al. (1999). Soluble pool of Aβ amyloid as a determinant of severity of
neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860–866. doi: 10.
1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Medler, K., and Gleason, E. L. (2002). Mitochondrial Ca(2+) buffering regulates
synaptic transmission between retinal amacrine cells. J. Neurophysiol. 87,
1426–1439. doi: 10.1152/jn.00627.2001
Messina, A., Reina, S., Guarino, F., and De Pinto, V. (2012). VDAC isoforms in
mammals. Biochim. Biophys. Acta 1818, 1466–1476. doi: 10.1016/j.bbamem.
2011.10.005
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 May 2015 | Volume 9 | Article 166
Arrázola et al. Wnt protects against mitochondrial damage
Miura, T., Nishihara, M., and Miki, T. (2009). Drug development targeting the
glycogen synthase kinase-3β (GSK-3β)-mediated signal transduction pathway:
role of GSK-3β in myocardial protection against ischemia/reperfusion injury. J.
Pharmacol. Sci. 109, 162–167. doi: 10.1254/jphs.08r27fm
Miura, T., and Tanno, M. (2010). Mitochondria and GSK-3β in cardioprotection
against ischemia/reperfusion injury. Cardiovasc. Drugs Ther. 24, 255–263.
doi: 10.1007/s10557-010-6234-z
Miyamoto, S., Murphy, A. N., and Brown, J. H. (2008). Akt mediates
mitochondrial protection in cardiomyocytes through phosphorylation of
mitochondrial hexokinase-II. Cell Death Differ. 15, 521–529. doi: 10.1038/sj.
cdd.4402285
Moreira, P. I., Santos, M. S., Moreno, A., and Oliveira, C. (2001). Amyloid β-
peptide promotes permeability transition pore in brain mitochondria. Biosci.
Rep. 21, 789–800. doi: 10.1023/A:1015536808304
Moreira, P. I., Santos, M. S., Moreno, A., Rego, A. C., andOliveira, C. (2002). Effect
of amyloid beta-peptide on permeability transition pore: a comparative study.
J. Neurosci. Res. 69, 257–267. doi: 10.1002/jnr.10282
Moreira, P. I., Santos, M. S., and Oliveira, C. R. (2007). Alzheimer’s disease: a
lesson from mitochondrial dysfunction. Antioxid. Redox Signal. 9, 1621–1630.
doi: 10.1089/ars.2007.1703
Morgan, C., Colombres, M., Nuñez, M. T., and Inestrosa, N. C. (2004). Structure
and function of amyloid in Alzheimer’s disease. Prog. Neurobiol. 74, 323–349.
doi: 10.1016/j.pneurobio.2004.10.004
Morris, R. L., and Hollenbeck, P. J. (1993). The regulation of bidirectional
mitochondrial transport is coordinated with axonal outgrowth. J. Cell Sci.
104(Pt. 3), 917–927.
Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of
Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol.
Imaging 32, 486–510. doi: 10.1007/s00259-005-1762-7
Muirhead, K. E. A., Borger, E., Aitken, L., Conway, S. J., and Gunn-
Moore, F. J. (2010). The consequences of mitochondrial amyloid beta-
peptide in Alzheimer’s disease. Biochem. J. 426, 255–270. doi: 10.1042/BJ200
91941
Newmeyer, D. D., and Ferguson-Miller, S. (2003). Mitochondria: releasing power
for life and unleashing the machineries of death. Cell 112, 481–490. doi: 10.
1016/S0092-8674(03)00116-8
Nishihara, M., Miura, T., Miki, T., Tanno, M., Yano, T., Naitoh, K., et al. (2007).
Modulation of the mitochondrial permeability transition pore complex in
GSK-3β-mediated myocardial protection. J. Mol. Cell. Cardiol. 43, 564–570.
doi: 10.1016/j.yjmcc.2007.08.010
Oliva, C. A., Vargas, J. Y., and Inestrosa, N. C. (2013). Wnts in adult brain: from
synaptic plasticity to cognitive deficiencies. Front. Cell. Neurosci. 7:224. doi: 10.
3389/fncel.2013.00224
Paula-Lima, A. C., Adasme, T., SanMartín, C., Sebollela, A., Hetz, C., Carrasco,
M. A., et al. (2011). Amyloid β-peptide oligomers stimulate RyR-mediated
Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons
and prevent RyR-mediated dendritic spine remodeling produced by BDNF.
Antioxid. Redox Signal. 14, 1209–1223. doi: 10.1089/ars.2010.3287
Petronilli, V., Penzo, D., Scorrano, L., Bernardi, P., and Di Lisa, F. (2001). The
mitochondrial permeability transition, release of cytochrome c and cell death.
Correlation with the duration of pore openings in situ. J. Biol. Chem. 276,
12030–12034. doi: 10.1074/jbc.m010604200
Qi, X., Disatnik, M.-H., Shen, N., Sobel, R. A., and Mochly-Rosen, D. (2011).
Aberrant mitochondrial fission in neurons induced by protein kinase Cdelta
under oxidative stress conditions in vivo. Mol. Biol. Cell 22, 256–265. doi: 10.
1091/mbc.E10-06-0551
Quintanilla, R. A., Muñoz, F. J., Metcalfe, M. J., Hitschfeld, M., Olivares, G.,
Godoy, J. A., et al. (2005). Trolox and 17beta-estradiol protect against amyloid
beta-peptide neurotoxicity by a mechanism that involves modulation of the
Wnt signaling pathway. J. Biol. Chem. 280, 11615–11625. doi: 10.1074/jbc.
m411936200
Rao, V. K., Carlson, E. A., and Yan, S. S. (2014). Mitochondrial permeability
transition pore is a potential drug target for neurodegeneration. Biochim.
Biophys. Acta 1842, 1267–1272. doi: 10.1016/j.bbadis.2013.09.003
Rasola, A., Sciacovelli, M., Chiara, F., Pantic, B., Brusilow, W. S., and Bernardi,
P. (2010a). Activation of mitochondrial ERK protects cancer cells from death
through inhibition of the permeability transition. Proc. Natl. Acad. Sci. U S A
107, 726–731. doi: 10.1073/pnas.0912742107
Rasola, A., Sciacovelli, M., Pantic, B., and Bernardi, P. (2010b). Signal transduction
to the permeability transition pore. FEBS Lett. 584, 1989–1996. doi: 10.1016/j.
febslet.2010.02.022
Reddy, P. H. (2006). Amyloid precursor protein-mediated free radicals and
oxidative damage: implications for the development and progression of
Alzheimer’s disease. J. Neurochem. 96, 1–13. doi: 10.1111/j.1471-4159.2005.
03530.x
Reddy, P. H. (2009). Amyloid beta, mitochondrial structural and functional
dynamics in Alzheimer’s disease. Exp. Neurol. 218, 286–292. doi: 10.1016/j.
expneurol.2009.03.042
Reddy, P. H. (2013). Amyloid β-induced glycogen synthase kinase 3β
phosphorylated VDAC1 in Alzheimer’s disease: implications for synaptic
dysfunction and neuronal damage. Biochim. Biophys. Acta 1832, 1913–1921.
doi: 10.1016/j.bbadis.2013.06.012
Robey, R. B., and Hay, N. (2006). Mitochondrial hexokinases, novel mediators of
the antiapoptotic effects of growth factors and Akt. Oncogene 25, 4683–4696.
doi: 10.1038/sj.onc.1209595
Rojo, M., Legros, F., Chateau, D., and Lombès, A. (2002). Membrane topology and
mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the
transmembrane GTPase Fzo. J. Cell Sci. 115, 1663–1674.
Ross, C. A., and Poirier, M. A. (2005). Opinion: what is the role of protein
aggregation in neurodegeneration?Nat. Rev. Mol. Cell Biol. 6, 891–898. doi: 10.
1038/nrm1742
Rosso, S. B., and Inestrosa, N. C. (2013). WNT signaling in neuronal maturation
and synaptogenesis. Front. Cell. Neurosci. 7:103. doi: 10.3389/fncel.2013.00103
Rosso, S. B., Sussman, D., Wynshaw-Boris, A., and Salinas, P. C. (2005). Wnt
signaling through Dishevelled, Rac and JNK regulates dendritic development.
Nat. Neurosci. 8, 34–42. doi: 10.1038/nn1374
Ruthel, G., and Hollenbeck, P. J. (2003). Response of mitochondrial traffic to axon
determination and differential branch growth. J. Neurosci. 23, 8618–8624.
Sakono, M., and Zako, T. (2010). Amyloid oligomers: formation and toxicity of Aβ
oligomers. FEBS J. 277, 1348–1358. doi: 10.1111/j.1742-4658.2010.07568.x
Salinas, P. C., and Zou, Y. (2008). Wnt signaling in neural circuit assembly. Annu.
Rev. Neurosci. 31, 339–358. doi: 10.1146/annurev.neuro.31.060407.125649
Sanmartin, C. D., Adasme, T., Hidalgo, C., and Paula-Lima, A. C. (2012).
The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation
induced by soluble amyloid-β peptide oligomers.Neurodegener. Dis. 10, 34–37.
doi: 10.1159/000334901
Saraiva, L. M., Seixas da Silva, G. S., Galina, A., da-Silva, W. S., Klein, W. L.,
Ferreira, S. T., et al. (2010). Amyloid-β triggers the release of neuronal
hexokinase 1 from mitochondria. PLoS One 5:e15230. doi: 10.1371/journal.
pone.0015230
Schinzel, A. C., Takeuchi, O., Huang, Z., Fisher, J. K., Zhou, Z., Rubens, J., et al.
(2005). Cyclophilin D is a component of mitochondrial permeability transition
andmediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad.
Sci. U S A 102, 12005–12010. doi: 10.1073/pnas.0505294102
Schon, E. A., and Przedborski, S. (2011). Mitochondria: the next
(neurode)generation. Neuron 70, 1033–1053. doi: 10.1016/j.neuron.2011.
06.003
Sheng, Z.-H., and Cai, Q. (2012). Mitochondrial transport in neurons: impact on
synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13, 77–93.
doi: 10.1038/nrn3156
Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., and
Arbel, N. (2010). VDAC, a multi-functional mitochondrial protein regulating
cell life and death. Mol. Aspects Med. 31, 227–285. doi: 10.1016/j.mam.2010.
03.002
Silva-Alvarez, C., Arrázola, M. S., Godoy, J. A., Ordenes, D., and Inestrosa,
N. C. (2013). Canonical Wnt signaling protects hippocampal neurons from Aβ
oligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics.
Front. Cell. Neurosci. 7:97. doi: 10.3389/fncel.2013.00097
Singh, P., Suman, S., Chandna, S., and Das, T. K. (2009). Possible role of
amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in
mitochondrial dysfunction of Alzheimer’s disease. Bioinformation 3, 440–445.
doi: 10.6026/97320630003440
Smirnova, E., Griparic, L., Shurland, D. L., and van der Bliek, A. M.
(2001). Dynamin-related protein Drp1 is required for mitochondrial division
in mammalian cells. Mol. Biol. Cell 12, 2245–2256. doi: 10.1091/mbc.
12.8.2245
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 May 2015 | Volume 9 | Article 166
Arrázola et al. Wnt protects against mitochondrial damage
Song, Z., Ghochani, M., McCaffery, J. M., Frey, T. G., and Chan, D. C. (2009).
Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane
fusion.Mol. Biol. Cell 20, 3525–3532. doi: 10.1091/mbc.E09-03-0252
Spät, A., Szanda, G., Csordás, G., and Hajnóczky, G. (2008). High- and low-
calcium-dependent mechanisms of mitochondrial calcium signalling. Cell
Calcium 44, 51–63. doi: 10.1016/j.ceca.2007.11.015
Stambolic, V., and Woodgett, J. R. (1994). Mitogen inactivation of glycogen
synthase kinase-3 β in intact cells via serine 9 phosphorylation. Biochem. J.
303(Pt. 3), 701–704.
Stutzmann, G. E., Smith, I., Caccamo, A., Oddo, S., Parker, I., and Laferla,
F. (2007). Enhanced ryanodine-mediated calcium release in mutant PS1-
expressing Alzheimer’s mouse models. Ann. N Y Acad. Sci. 1097, 265–277.
doi: 10.1196/annals.1379.025
Su, B., Wang, X., Zheng, L., Perry, G., Smith, M. A., and Zhu, X. (2010). Abnormal
mitochondrial dynamics and neurodegenerative diseases. Biochim. Biophys.
Acta 1802, 135–142. doi: 10.1016/j.bbadis.2009.09.013
Supnet, C., and Bezprozvanny, I. (2010). Neuronal calcium signaling,
mitochondrial dysfunction and Alzheimer’s disease. J. Alzheimers Dis.
20(Suppl. 2), S487–S498. doi: 10.3233/JAD-2010-100306
Swerdlow, R. H., Burns, J. M., and Khan, S. M. (2010). The Alzheimer’s disease
mitochondrial cascade hypothesis. J. Alzheimers Dis. 20(Suppl. 2), S265–S279.
doi: 10.3233/JAD-2010-100339
Szalai, G., Krishnamurthy, R., and Hajnóczky, G. (1999). Apoptosis driven by
IP(3)-linked mitochondrial calcium signals. EMBO J. 18, 6349–6361. doi: 10.
1093/emboj/18.22.6349
Taguchi, N., Ishihara, N., Jofuku, A., Oka, T., and Mihara, K. (2007).
Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in
mitochondrial fission. J. Biol. Chem. 282, 11521–11529. doi: 10.1074/jbc.
m607279200
Tamura, Y., Itoh, K., and Sesaki, H. (2011). SnapShot: mitochondrial dynamics.
Cell 145, 1158–1158.e1. doi: 10.1016/j.cell.2011.06.018
Tanno, M., Kuno, A., Ishikawa, S., Miki, T., Kouzu, H., Yano, T., et al.
(2014). Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger
of permeability transition, is kinase activity-dependent and mediated by
interaction with voltage-dependent anion channel 2 (VDAC2). J. Biol. Chem.
289, 29285–29296. doi: 10.1074/jbc.M114.563924
Toledo, E. M., and Inestrosa, N. C. (2010). Activation of Wnt signaling by lithium
and rosiglitazone reduced spatial memory impairment and neurodegeneration
in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease.
Mol. Psychiatry 15, 272–285, 228. doi: 10.1038/mp.2009.72
Tsujimoto, Y., and Shimizu, S. (2007). Role of the mitochondrial membrane
permeability transition in cell death. Apoptosis 12, 835–840. doi: 10.
1007/s10495-006-0525-7
Varela-Nallar, L., Alfaro, I. E., Serrano, F. G., Parodi, J., and Inestrosa, N. C. (2010).
Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation
and function of glutamatergic synapses. Proc. Natl. Acad. Sci. U S A 107,
21164–21169. doi: 10.1073/pnas.1010011107
Varela-Nallar, L., and Inestrosa, N. C. (2013). Wnt signaling in the regulation
of adult hippocampal neurogenesis. Front. Cell. Neurosci. 7:100. doi: 10.
3389/fncel.2013.00100
Vargas, J. Y., Fuenzalida, M., and Inestrosa, N. C. (2014). In vivo activation of
Wnt signaling pathway enhances cognitive function of adult mice and reverses
cognitive deficits in an Alzheimer’s disease model. J. Neurosci. 34, 2191–2202.
doi: 10.1523/jneurosci.0862-13.2014
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S.,
et al. (2002). Naturally secreted oligomers of amyloid beta protein potently
inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539.
doi: 10.1038/416535a
Wang, H., Song, P., Du, L., Tian, W., Yue, W., Liu, M., et al. (2011). Parkin
ubiquitinates Drp1 for proteasome-dependent degradation: implication of
dysregulated mitochondrial dynamics in Parkinson disease. J. Biol. Chem. 286,
11649–11658. doi: 10.1074/jbc.m110.144238
Wang, X., Su, B., Lee, H., Li, X., Perry, G., Smith, M. A., et al. (2009). Impaired
balance of mitochondrial fission and fusion in Alzheimer’s disease. J. Neurosci.
29, 9090–9103. doi: 10.1523/JNEUROSCI.1357-09.2009
Wang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y.,
et al. (2008). Amyloid-beta overproduction causes abnormal mitochondrial
dynamics via differential modulation of mitochondrial fission/fusion proteins.
Proc. Natl. Acad. Sci. U S A 105, 19318–19323. doi: 10.1073/pnas.08048
71105
Wang, X., Yan, M. H., Fujioka, H., Liu, J., Wilson-delfosse, A., Chen, S. G.,
et al. (2012). LRRK2 regulates mitochondrial dynamics and function through
direct interaction with DLP1. Hum. Mol. Genet. 21, 1931–1944. doi: 10.
1093/hmg/dds003
Westermann, B. (2010). Mitochondrial fusion and fission in cell life and death.
Nat. Rev. Mol. Cell Biol. 11, 872–884. doi: 10.1038/nrm3013
Willert, K., and Nusse, R. (2012). Wnt proteins. Cold Spring Harb. Perspect. Biol.
4:a007864. doi: 10.1101/cshperspect.a007864
Wilson, T. J., Slupe, A. M., and Strack, S. (2013). Cell signaling and mitochondrial
dynamics: implications for neuronal function and neurodegenerative disease.
Neurobiol. Dis. 51, 13–26. doi: 10.1016/j.nbd.2012.01.009
Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., et al.
(2001). Intraneuronal Aβ accumulation precedes plaque formation in beta-
amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci.
Lett. 306, 116–120. doi: 10.1016/s0304-3940(01)01876-6
Xie, W., and Chung, K. K. K. (2012). Alpha-synuclein impairs normal dynamics of
mitochondria in cell and animal models of Parkinson’s disease. J. Neurochem.
122, 404–414. doi: 10.1111/j.1471-4159.2012.07769.x
Yan, M. H., Wang, X., and Zhu, X. (2013). Mitochondrial defects and oxidative
stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 62,
90–101. doi: 10.1016/j.freeradbiomed.2012.11.014
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., and Brinton, R. D.
(2009). Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in
female mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 106,
14670–14675. doi: 10.1073/pnas.0903563106
Yoon, Y., Galloway, C. A., Jhun, B. S., and Yu, T. (2011). Mitochondrial dynamics
in diabetes. Antioxid. Redox Signal. 14, 439–457. doi: 10.1089/ars.2010.3286
Youle, R. J., and van der Bliek, A. M. (2012). Mitochondrial fission, fusion and
stress. Science 337, 1062–1065. doi: 10.1126/science.1219855
Yu, C., Nwabuisi-Heath, E., Laxton, K., and Ladu,M. J. (2010). Endocytic pathways
mediating oligomeric Aβ42 neurotoxicity. Mol. Neurodegener. 5:19. doi: 10.
1186/1750-1326-5-19
Zorov, D. B., Juhaszova, M., Yaniv, Y., Nuss, H. B., Wang, S., and Sollott,
S. J. (2009). Regulation and pharmacology of the mitochondrial permeability
transition pore. Cardiovasc. Res. 83, 213–225. doi: 10.1093/cvr/cvp151
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Arrázola, Silva-Alvarez and Inestrosa. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution and reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 May 2015 | Volume 9 | Article 166
